Johns Hopkins Diabetes Guide
Lorcaserin
INDICATIONS
FDA
FDA
- Indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m2, or overweight patients with a BMI ≥ 27 kg/m2 in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea) for weight loss and maintenance of weight loss
- Approved for use only in conjunction with a reduced-calorie diet and a program of regular exercise
- Approved for adults, age 18 and older
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 6, 2017
Citation
Dalpoas, Stacy E, et al. "Lorcaserin." Johns Hopkins Diabetes Guide, The Johns Hopkins University, 2017. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547169/all/Lorcaserin.
Dalpoas SE, Lee C, Pinto B. Lorcaserin. Johns Hopkins Diabetes Guide. The Johns Hopkins University; 2017. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547169/all/Lorcaserin. Accessed October 12, 2025.
Dalpoas, S. E., Lee, C., & Pinto, B. (2017). Lorcaserin. In Johns Hopkins Diabetes Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547169/all/Lorcaserin
Dalpoas SE, Lee C, Pinto B. Lorcaserin [Internet]. In: Johns Hopkins Diabetes Guide. The Johns Hopkins University; 2017. [cited 2025 October 12]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547169/all/Lorcaserin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Lorcaserin
ID - 547169
A1 - Dalpoas,Stacy,Pharm.D., BCPS
AU - Lee,Clare,M.D., MHS
AU - Pinto,Brian,Pharm.D
Y1 - 2017/09/06/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547169/all/Lorcaserin
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
